GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
Locked. A moderator closed replies on this one. It stays up because the content above the argument is worth keeping.
707
c/glp1eu·posted 1 year ago by u/marisol_frisk

[Discussion] Apotheke is doing more work than we give it credit for

Discussion Cold Box ×1

The title is the argument: Apotheke is doing more work than we give it credit for. Here is the rest of it.

Nothing here is medical or legal advice, and eligibility questions have national answers that a pharmacist where you live can give you in minutes.

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.

984 up / 277 down78% upvoted31 commentsid wa51yb8 Feb 2025

31 comments

13 in this archive, depth 3

best — the order this archive was captured in

u/oskar_malinowski0 points·1 year ago

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

replysharereportpermalink
u/osman_brandt1 point·1 year ago

Pharmacy margins and dispensing fees are regulated nationally, which explains price differences that otherwise look arbitrary.

replysharereportpermalink
[removed]1 point·1 year ago

[removed by moderator]

replysharereportpermalink
u/fabio_ibarra1 point·1 year ago

Correction: that is the authorisation position, and the question was about reimbursement. Different bodies, different answers.

replysharereportpermalink
u/aa_analysis_andy1 point·1 year ago

Not convinced — cross-border prescription recognition is narrower than you are describing and the exceptions matter.

replysharereportpermalink
u/vito_chowdhury46 points·1 year ago

Careful, that guidance is from a different country and this thread is asking about somewhere else entirely.

replysharereportpermalink
u/ahmed_rasmussen37 points·1 year ago

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

replysharereportpermalink
u/plateau_patrol15 points·1 year ago·edited

Careful, that guidance is from a different country and this thread is asking about somewhere else entirely.

This is the split the whole board depends on. Authorisation is European; payment is national.

replysharereportpermalink
u/emeka_beaulieu11 points·1 year ago

Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences. Those are decided by different bodies with different processes.

replysharereportpermalink
u/milan_mensah28 points·1 year ago

Yes. Pack sizes differ enough that per-month price comparisons across borders need to be normalised before they mean anything.

replysharereportpermalink
u/pavel_kimani0 points·1 year ago

Yes.

milan_mensah is right about cross-border recognition being narrower than the summaries suggest.

replysharereportpermalink
u/fabio_ibarra23 points·1 year ago

That is an authorisation question and you have answered a reimbursement one. They are decided by different bodies.

replysharereportpermalink
u/cormac_erdogan8 points·1 year ago

That shortage notice was national and does not apply where the question is coming from.

replysharereportpermalink
About c/glp1eu

European access, country by country: prescription routes, reimbursement reality, pharmacy stock, EMA notices and the fact that "EU rules" is usually a national question wearing a European hat.

32kmembers
62submissions
Apr 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/glp1eu rules
  1. Tag your country in the title. Bare "EU" questions get a template reply.
  2. Pricing posts need the date and the currency.
  3. EMA and national agency claims need a citation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.